{"id":"W4379791997","doi":"10.1200/jco.23.00233","title":"Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":132,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Olaparib; Prostate cancer; Pembrolizumab; Oncology; Internal medicine; Randomized controlled trial; Biomarker; Open label; PARP inhibitor; Metastatic breast cancer; Cancer; Immunotherapy; Breast cancer; Poly ADP ribose polymerase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004965931,0.0002404983,0.002471375,0.0001813656,0.0002242787,0.00008390643,0.0002421905,0.0001626182,0.000048946],"category_scores_gemma":[0.002851089,0.0001103789,0.0002406238,0.0005058957,0.0005732384,0.0001980971,0.00006565975,0.0005534405,0.000002544462],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002568017,"about_ca_system_score_gemma":0.004660472,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001848044,"about_ca_topic_score_gemma":0.0002768286,"domain_scores_codex":[0.9953399,0.001092992,0.002277609,0.0003179305,0.0005085486,0.0004630392],"domain_scores_gemma":[0.9908268,0.005648832,0.001717442,0.0002012662,0.001199783,0.0004058252],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9354349,0.003082188,0.0004836408,0.00007533535,0.00262171,0.0002491706,0.0002956932,0.000003681326,0.0001109373,0.00002811852,0.004214456,0.0534002],"study_design_scores_gemma":[0.9307252,0.05704127,0.002348887,0.0001684984,0.002474634,0.00004073969,0.00009437538,0.001038284,0.000035442,0.0001679316,0.005744333,0.0001204014],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.984359,0.001056558,0.00002722707,0.005414107,0.000475629,0.008432508,0.00008209085,0.00001955617,0.0001332913],"genre_scores_gemma":[0.9913104,0.004638003,0.0005811329,0.0003562409,0.0003123884,0.0008160268,0.0001656906,0.00004093694,0.001779141],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05395909,"threshold_uncertainty_score":0.8267477,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1857888830145629,"score_gpt":0.51321039237129,"score_spread":0.3274215093567271,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}